Hemolytic uremic syndrome induced by infusion of oxaliplatin: a case report

Patrizia Racca1, Rosella Spadi1, Gianluca Fora1, Laura Fanchini1, Giuliana Ritorto2, Laura Ferrari1, Francesco Pinta1, Patrizia Lista2, and Libero Ciuffreda2

1SSCVD Colorectal Cancer Unit, and 2SC Medical Oncology 1, AOU San Giovanni Battista, Turin, Italy.

ABSTRACT

Introduction. Oxaliplatin is a third-generation platinum compound with proven antitumor activity in the treatment of colorectal cancer. The occurrence of life-threatening hemolytic uremic syndrome has been observed after oxaliplatin therapy. The kind of tumor and treatment modalities seem to influence the onset of hemolytic uremic syndrome.

Methods. The clinical course of the case is reviewed and compared with reports of other similar cases in the literature.

Results. We describe the development of hemolytic uremic syndrome as a result of prolonged oxaliplatin treatment of a colon cancer patient.

Conclusions. Although this rare event requires the concurrence of other unknown factors, it should be considered in a decision-making setting.

Key words: chemotherapy, colorectal cancer, hemolytic uremic syndrome, oxaliplatin.

Author’s conflicts of interest: none.

Correspondence to: Dr.ssa Patrizia Racca, MD, Chief, SSCVD Colorectal Cancer Unit, Medical Oncology 1, AOU S. Giovanni Battista, Cso Bramante 88, 10126 Turin, Italy.
Tel 0039-011-633-5504; fax 0039-011-633-4476; e-mail pracca@molinette.piemonte.it

Received October 4, 2010; accepted December 10, 2010.